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HEPATIC CRYOTHERAPY FOR CANCER:
A REVIEWAND CRITIQUE
ABSTRACT
Polk, W., Fong, Y., Karpeh, M. and Blumgart, L.H. (1995) A technique for the use of
cyrosurgery to assisthepatic resection. Journal oftheAmerican College ofSurgeons; 180:
171-176
BACKGROUND: Wedge or other nonanatomic hepatic resections, performed in an
attempt to spare functional parenchyma, often are not accomplished with clear resection
margins and may be complicated by hemorrhage from the depth of the resection.
STUDY DESIGN: The current study describes a technique of cryoassisted hepatic
resection that allows for controlled resection with well-defined margins. The early
experience in managing 16 tumors in 13 patients is reported.
RESULTS: A cryoprobe is inserted into the tumor and freezing performed to a pre-
determined resection margin using ultrasound control. The ice ball, so formed, is then
maintained and excised. The management of these 13 patients was associated with one
intraoperative and two postoperative complications, including a death of a patient with
cirrhosis who had infected ascites and died as a result of hepatic failure.
CONCLUSIONS: Cryoassisted hepatic resection seems to be safe and allows resection
with good tumor clearance and maximal preservation of functional parenchyma.
J. Am. Coll. Surg., 1995, 180: 171-176.
KEYWORDS: Hepatic resection cryosurgery hepatic colorectal
metastases primary hepatocellular carcinoma.
PAPERDISCUSSION
The use ofcold to destroy cancers was described about
150 years and was well understood 20 years ago but
advances in ultrasound and cryomachine/probe tech-
nology have, however, allowed this to be applied to
some deep cancers, including prostate, kidney and the
topic of this essay, the liver. Before considering the
paper of Polk et al. in detail, perhaps we could briefly
review what is known ofhepatic cryotherapy, and our
own experience.
INDICATIONS
1) Hepatoma
There is a sizeable experience of cryotherapy for
hepatoma in China with approximately 20%five-year
survival and no operative mortality. These patients
did, however, receive other treatments, making the
data difficult to interpret. The principal advantage of
cryotherapy in this patient group is the preservation of
hepatic parenchyma.
2) Liver Metastases From Colorectal Cancer
This indication has been responsible for the majority of
patients treated in the westen world5. My own experi-
ence is of 162 separate procedures in 149 patients,
almost exclusively in unresectable patients, the few
exceptions being mainly patients considered high risk
for resection because of cardiovascular disease. Our
technique is described elsewhere6. We have seen one
thirty-day death (myocardial infarction) and one late
death due to hepatic abscess associated with concur-
rent colectomy at 10 weeks.
Limited perioperative morbidity and short hospital
stay was seen even in our early experience7. We have
not had the devastating cryoshock phenomenon de-
scribed by the Pittsburgh group but we do not do a
double freeze with complete thaw. There is no doubtHPB INTERNATIONAL 119
that a twin freeze thaw has a considerably more de-
structive cellular effect9’1 but even our partial twin
freeze thaw produces greater evidence of hepato-
cellular injury and dramatic fall in platelet countTM.
We have chosen to only re-freeze the outer 1 cm of a
cryolesion, which is the least definitively destroyed.
The issue of the utility of regional chemotherapy fol-
lowing cryotherapy is covered elsewhere
13 but as this
therapy is now proven to improve survival4’5 and is
reviewed elsewhere 16, we believe that, in patients with
more than three lessions, it is mandatory.
CEA reduction has been seen in almost all secretors
(82%) and the size ofreduction is ofmedian 84% ofthe
preoperative value, the percentage reduction has been
highly prognostic of survival 13. In more than one half
of the CEA responders, this was to the normal range
and median survival in this group is in excess of 1000
days, which has to be regarded as most encouraging
in patients with multiple (median 3.9) unresectable
hepatic metastases 17.
The Boston group have mainly treated patients with
operable lesions. Of34 patients treated by cryotherapy
alone, there were 1-3 lesions (mean 1.4)5’18 and, of the
first 49 patients treated in Boston, 35 were considered
to have no gross residual disease after cryotherapy. Of
these, 13 have died, although three deaths were from
non-malignant casuses and, of the remaining 22, only
36% appear tumor free at 3-88 months (median 12). I
do not yet believe that this follow-up is adequate for
cryotherapy to be advocated in patients with operable
lesions who have no medical risk factors for resection.
I also believe it is premature to mount controlled trails
to address this issue. Liver resection can achieve five-
year survival in almost a half of our patients and with
a mortality ofwell under 5%, so what does cryotherapy
have to offer to this group? Even when five-year sur-
vival of larger numbers of patients with operable dis-
ease treated by cryotherapy is known, will cryotherapy
offer any significant reduction in risk ofthe procedure:
in skilled hands, I doubt it.
3) Neuroendocrine
Although a rare tumour, the role of cryotherapy for
neuroendocrine liver metastases is perhaps most excit-
ing and has involved some extensive and time-consum-
ing surgery. We have to date treated without mortality
six patients with unresectable hepatic metastases from
neuroendocrine tumor. Not only have we seen excel-
lent clinical, radiologic and tumor marker results
9 but
the length of benefit in most of this group of patients
seems to be considerable.
4) Adjunct to liver resection: edgefreeze/
contralateral disease
We have used cryotherapy in a different way than the
featured paper to treat involved or inadequate hepatic
resection margins, where disease free survival is only
20% of the former group at year2, and to treat
contralateral disease following lobectomy
21 with to
date an apparently lower risk of edge recurrence than
might be expected. Only two of twelve edge freeze
patients have recurrence at a median of 14 months
and, whilst the data is less mature, at least some of the
contralobe freeze patients remain tumor free.
5) Future
Hepatic cryotherapy has already been done under
laparoscopic guidance
22 but, although we have failed
to produce gas embolism in a rabbit model23, I remain
concerned about the efficacy and safety ofthis (it really
bleeds, sometimes) and also the ease ofplacement ofan
arterial perfusion device.
Cryotherapy does offer the ability to destroy large
volumes ofliver with relative safety. Our data suggests
that the adequacy of tumor ablation, as measured by
CEA reduction, does affect survival. Indeed, the large
group whereCEA returns to normal appear (at least as
far as three years) to have similar survival prospects to
patients who do have resectable disease. Cryotherapy
has been a very useful adjunct to liver resection in our
hands, although we have used it in a very different
manner than Blumgart’s group.
CRITIQUE
The use ofcryotherapy to ensure an adequate resection
margin is hard forme to understand. Cryotherapy does
take time, the equipment is expensive and it does have
intra-operative hazards of its own, even if some of the
postoperative sequelae of cryotherapy are avoided by
this iceballectomy. Clearly, the concept depends upon
the ultrasonographic skill of the operator because one
will be making ajudgement ofthe cm margin between
lesion edge and iceball edge on ultrasound and, of
course, lesion edge disappears as soon as it is enveloped
by iceball. It must be understood that this cm margin
needs to be on every margin ofthe tumor. The paper is
also largely devoid of meaningful data, in that there is
no effort to describe disease free recurrence. It is par-
ticularly disappointing that there is not even a measure
ofthe actual resection margins achieved, i.e., minimum
margin in each lesion. Perhaps it would be valuable if120 HPB INTERNATIONAL
compared with some retrospective data for wedges. The
contemporary condemnation of wedges in favour of
segmentally based resection is also basedupon the poor
blood loss record of wedges. It seems unlikely that the
described technique will alter this and there is not a
comprehensive description of the blood loss/transfu-
sion requirements of these patients in this paper.
The cryoablative role of hepatic cryotherapy may
well require more data to convince us but its role as a
handle or a fender bar would seem less likely to be of
importance, but I’ve been wrong before.
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